Blinatumomab Clinical Trials

34 actively recruiting trials across 12 locations

Also known as: 6-MP, 853426-35-4, AMG 103, AMG 103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Asparaginase, BLINCYTO, BLINCYTO®, Blina, Blincyto, Blino, Cycle 1, Cycle 2, Cyclophosphomide, Cytarabine, Daunorubicin, Dexamethasone, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Methotrexate, Prednisone, Vincristine

Filter by location:

Other9 trials

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Phase 3

Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

N/A

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

Phase 2

Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

Phase 2/3

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Phase 2

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Phase 3

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Phase 2/3

Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

Phase 2

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Phase 3

Houston, Texas7 trials

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

The University of Texas M. D. Anderson Cancer Center

Phase 2

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 2

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 2

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 1/2

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

MD Anderson Cancer Center

Phase 1/2

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

MD Anderson Cancer Center

Phase 1/2

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M D Anderson Cancer Center

Phase 2

Birmingham, Alabama6 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 3

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

University of Alabama at Birmingham Cancer Center

Phase 2

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital of Alabama

Phase 3

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

University of Alabama at Birmingham

Phase 1

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Chicago, Illinois2 trials

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

University of Chicago Comprehensive Cancer Center

Phase 1

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

University of Chicago Medicine Comprehensive Cancer Center

Phase 1/2

Memphis, Tennessee2 trials

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

St Jude Childrens Research Hospital

Phase 1/2

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 1

Phoenix, Arizona1 trial

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Phoenix Children's Hospital

Phase 1/2

Scottsdale, Arizona1 trial

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

HonorHealth Research and Innovation Institute

Phase 2

Duarte, California1 trial

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

City of Hope National Medical Center

Phase 1/2

Sacramento, California1 trial

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

University of California Davis Comprehensive Cancer Center

Phase 2

Atlanta, Georgia1 trial

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

Northside Hospital

Phase 2

Tulsa, Oklahoma1 trial

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Saint Francis Children's Hospital

Phase 2

Portland, Oregon1 trial

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

OHSU Knight Cancer Institute

Phase 1

Milwaukee, Wisconsin1 trial

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

Children's Hospital of Wisconsin

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.